Patient-Derived Cellular Models of Putative Antidepressants
推定抗抑郁药的患者衍生细胞模型
基本信息
- 批准号:9112189
- 负责人:
- 金额:$ 40.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-30 至 2020-09-29
- 项目状态:已结题
- 来源:
- 关键词:Antidepressive AgentsBiological AssayBiological MarkersBromodeoxyuridineCell LineCell LineageCell modelCellsComplementary and alternative medicineDNADataDermalDevelopmentDifferentiation AntigensDiseaseDisease modelDisease remissionEpigenetic ProcessExposure toFibroblastsFutureGene ExpressionGene Expression ProfileGenesHumanImageIn VitroIndividualInflammationInterleukin-6InterventionInvestigationMajor Depressive DisorderMeasuresMediatingMedicalMental DepressionMental disordersMethionineMitoticModelingMorbidity - disease rateNeurobiologyNeurogliaNeuronal PlasticityNeuronsOmega-3 Fatty AcidsParticipantPathologyPathway AnalysisPathway interactionsPatientsPharmaceutical PreparationsPhenotypePlacebo ControlPluripotent Stem CellsResourcesSignal TransductionStem cellsStressTestingTherapeutic EffectTimeTissuesTreatment EfficacyTreatment outcomeTumor Necrosis Factor-alphaarmbiobankbiosignaturecohortdevelopmental neurobiologydifferential expressioneffective therapyhigh throughput screeninghistone methylationin vitro Assayinduced pluripotent stem cellinflammatory markernerve stem cellneurogenesisneuropathologyneuroprotectionnovelnovel strategiesprecursor cellpsychosocialrandomized trialrelating to nervous systemresponsescreeningstem cell technologytreatment responseworking group
项目摘要
PROJECT 3 ABSTRACT: Major depressive disorder (MDD) remains one of the most prevalent and costly
medical disorders. A third or more of patients may not achieve symptomatic remission despite multiple
medication treatments; many other individuals are simply unable or unwilling to initiate prescription
pharmacologic or psychosocial treatment. Complementary and alternative medications (CAM) represent an
important option for such patients. In addition to understanding which CAM antidepressant strategies are
efficacious for depression as well as for stress, the aim of Project 1, it would be highly valuable to understand
the mechanisms by which certain CAM treatments exert their therapeutic effect. This understanding could
increase the acceptability of current treatments, allow better matching of patients with effective treatments, and
facilitate the investigation and development of novel CAM treatments. For standard antidepressant treatments,
multiple hypotheses regarding mechanisms of action have been developed. These include (i) promotion of
neuroplasticity, (ii) modulation of inflammation, and (iii) promotion of neurogenesis. To date, investigation of
these latter hypotheses has been hampered by a lack of direct models of human neurobiology – and
particularly neuropathology - amenable to rapid screening and quantitative functional assessment. That is, it
has not been possible to examine whether these hypotheses are supported in neural tissue from patients with
the particular disease targeted by these interventions. Progress in stem cell technology and developmental
neurobiology allows a novel strategy that forms the focus of Project 3. Dermal fibroblasts from 180 patient
participants in the randomized trial of Project One will be reprogrammed (transdifferentiated) to induced
neurons (iNs). Transcriptional profiles of these iN's will be compared after exposure to n-3 fatty acids, S-
adenosyl L-methionine (SAMe), or vehicle to test whether the two CAMs regulate genes related to
neuroplasticity (Aim 1a), and whether degree of modulation of neuroplasticity is associated with treatment
efficacy. In parallel, a subset (10 per treatment arm) of patient-derived fibroblasts will be reprogrammed to
induced pluripotent stem cells. These cell lines will then be differentiated into neuronal precursors and
ultimately to mature neurons. Work by this group and others indicates that it is possible to generate such cells
and incorporate them in high-throughput, quantitative functional assays to characterize phenotypes relevant to
antidepressant mechanism. Specifically, the hypothesis that n-3 fatty acids and SAMe modulate inflammatory
markers on neural-lineage cells (Aim 2a), and promote neurogenesis (Aim 2b), will be tested using validated
assays. The hypothesis that these mechanisms are associated with treatment efficacy will also be tested. In
addition to examining these primary hypotheses, this project will establish a critical resource for future
investigation of CAM compounds, a biobank of 180 fibroblasts and 30 pluripotent stem cells and neuronal
precursor cells, all derived from patients with MDD participating in Project 1's placebo-controlled investigations.
NARRATIVE
Major depressive disorder is a major contributor to morbidity worldwide, and existing treatments fail to yield
symptomatic remission in ~1/3 of patients. While Complementary and Alternative Medicine (CAM) compounds
are increasingly used to treat depression, and well-accepted by patients, their mechanisms of effect have not
been fully characterized. The proposed investigation will test specific hypotheses extending preliminary data
using unique patient-derived stem cells and induced neurons, while at the same timing establishing
biomarkers, biosignatures, and a biobank to facilitate future CAM studies.
项目3摘要:重度抑郁症(MDD)仍然是最普遍和最昂贵的疾病之一
医学疾病三分之一或更多的患者可能无法达到症状缓解,尽管有多种
药物治疗;许多其他人只是不能或不愿意开始处方
药物或心理治疗。补充和替代药物(CAM)是一种
这类患者的重要选择。除了了解哪些CAM抗抑郁药策略是
有效的抑郁症以及压力,项目1的目的,这将是非常有价值的了解
某些CAM治疗发挥其治疗效果的机制。这种理解可以
提高目前治疗的可接受性,使患者与有效治疗更好地匹配,
促进新型CAM治疗的研究和开发。对于标准的抗抑郁治疗,
已经提出了关于作用机制的多种假设。这些措施包括:(一)促进
神经可塑性,(ii)炎症的调节,和(iii)促进神经发生。迄今为止,
后一种假说由于缺乏人类神经生物学的直接模型而受到阻碍,
特别是神经病理学-适合于快速筛查和定量功能评估。即它
目前还不可能检查这些假设是否在患有神经系统疾病的患者的神经组织中得到支持。
这些干预措施所针对的特定疾病。干细胞技术与发育
神经生物学允许一种新的策略,形成项目3的重点。180例患者的真皮成纤维细胞
参与项目一随机试验的受试者将被重新编程(转分化),以诱导
神经元(iNs)。将在暴露于n-3脂肪酸、S-脂肪酸和N-脂肪酸后比较这些iN的转录谱。
腺苷L-甲硫氨酸(SAMe)或载体,以测试两种CAM是否调节与以下相关的基因:
神经可塑性(目的1a),以及神经可塑性的调节程度是否与治疗相关
功效同时,将对患者来源的成纤维细胞亚组(每个治疗组10个)进行重编程,
诱导多能干细胞然后这些细胞系将分化成神经元前体,
最终发育成成熟的神经元。这个小组和其他人的工作表明,
并将其纳入高通量定量功能测定中,以表征与以下相关的表型:
抗抑郁机制具体地说,假设n-3脂肪酸和SAMe调节炎症反应,
神经谱系细胞上的标志物(Aim 2a)和促进神经发生(Aim 2b),将使用经过验证的
测定。还将检验这些机制与治疗疗效相关的假设。在
除了检查这些主要假设外,该项目还将为未来的研究建立一个关键资源。
CAM化合物的研究,180个成纤维细胞和30个多能干细胞和神经元的生物库
前体细胞,均来自参与项目1安慰剂对照研究的MDD患者。
叙事
重度抑郁症是世界范围内发病率的主要原因,现有的治疗方法无法产生
约1/3的患者症状缓解。补充和替代医学(CAM)
越来越多地被用于治疗抑郁症,并被患者所接受,但其作用机制还没有
被充分定性。拟议的调查将测试具体的假设,
使用独特的患者源性干细胞和诱导神经元,同时建立
生物标志物、生物特征和生物库,以促进未来的CAM研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEPHEN J HAGGARTY其他文献
STEPHEN J HAGGARTY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEPHEN J HAGGARTY', 18)}}的其他基金
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets
结节性硬化症患者 iPSC 衍生的 NPC 和 NCC 作为人体模型系统来识别新靶点
- 批准号:
10408151 - 财政年份:2019
- 资助金额:
$ 40.7万 - 项目类别:
Tuberous Sclerosis Complex Patients iPSC-derived NPCs and NCCs as Human Model Systems to Identify Novel Targets
结节性硬化症患者 iPSC 衍生的 NPC 和 NCC 作为人体模型系统来识别新靶点
- 批准号:
10641016 - 财政年份:2019
- 资助金额:
$ 40.7万 - 项目类别:
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi
PGRN 调节剂作为额颞叶痴呆新疗法的验证
- 批准号:
9674183 - 财政年份:2018
- 资助金额:
$ 40.7万 - 项目类别:
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi
PGRN 调节剂作为额颞叶痴呆新疗法的验证
- 批准号:
10480905 - 财政年份:2018
- 资助金额:
$ 40.7万 - 项目类别:
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi
PGRN 调节剂作为额颞叶痴呆新疗法的验证
- 批准号:
10237945 - 财政年份:2018
- 资助金额:
$ 40.7万 - 项目类别:
Validation of Modulators of PGRN as Novel Therapeutics for Frontotemporal Dementi
PGRN 调节剂作为额颞叶痴呆新疗法的验证
- 批准号:
9791027 - 财政年份:2018
- 资助金额:
$ 40.7万 - 项目类别:
Epigenetic Radiotracers for PET Imaging: Isoform-SelectiveHDAC Probes
用于 PET 成像的表观遗传放射性示踪剂:异构体选择性 HDAC 探针
- 批准号:
9915983 - 财政年份:2017
- 资助金额:
$ 40.7万 - 项目类别:
Epigenetic Radiotracers for PET Imaging: Isoform-SelectiveHDAC Probes
用于 PET 成像的表观遗传放射性示踪剂:异构体选择性 HDAC 探针
- 批准号:
9379945 - 财政年份:2017
- 资助金额:
$ 40.7万 - 项目类别:
Patient-Derived Cellular Models of Putative Antidepressants
推定抗抑郁药的患者衍生细胞模型
- 批准号:
9136769 - 财政年份:2015
- 资助金额:
$ 40.7万 - 项目类别:
Patient-Derived Cellular Models of Putative Antidepressants
推定抗抑郁药的患者衍生细胞模型
- 批准号:
9761448 - 财政年份:2015
- 资助金额:
$ 40.7万 - 项目类别:
相似海外基金
Establishment of a new biological assay using Hydra nematocyst deployment
利用水螅刺丝囊部署建立新的生物测定方法
- 批准号:
520728-2017 - 财政年份:2017
- 资助金额:
$ 40.7万 - 项目类别:
University Undergraduate Student Research Awards
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10368760 - 财政年份:2017
- 资助金额:
$ 40.7万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10669539 - 财政年份:2017
- 资助金额:
$ 40.7万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9570142 - 财政年份:2017
- 资助金额:
$ 40.7万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9915803 - 财政年份:2017
- 资助金额:
$ 40.7万 - 项目类别:
COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).
COVID-19 补充工作:用于确定组织特异性吸收电离辐射剂量的护理点生物测定(生物剂量计)。
- 批准号:
10259999 - 财政年份:2017
- 资助金额:
$ 40.7万 - 项目类别:
Drug discovery based on a new biological assay system using Yeast knock-out strain collection
基于使用酵母敲除菌株收集的新生物测定系统的药物发现
- 批准号:
21580130 - 财政年份:2009
- 资助金额:
$ 40.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2005
- 资助金额:
$ 40.7万 - 项目类别:
Postdoctoral Fellowships
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2004
- 资助金额:
$ 40.7万 - 项目类别:
Postdoctoral Fellowships